Redx has recently confirmed they'll be restarting a Phase I/IIa clinical trial for the drug in the first half of next year – at a much reduced dose.
Redx Pharma's chief medical officer discusses lead oncology drug RXC004
Quick facts: Redx Pharma Plc
Price: 7.75 GBX
Market Cap: £9.8 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Redx Pharma Plc named herein, including the promotion by the Company of Redx Pharma Plc in any Content on the Site, the Company receives from...FOR OUR FULL DISCLAIMER CLICK HERE